The importance of animal models in tumor immunity and immunotherapy

Current Opinion in Genetics and Development

Volumn 24, Issue 1, 2014, Pages 46-51

  Budhu, Sadna ^a   Wolchok, Jedd ^a,b   Merghoub, Taha ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DABRAFENIB; IPILIMUMAB; NIVOLUMAB; SIPULEUCEL T; TRAMETINIB;

CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER RESEARCH; DISEASE MODEL; GENETICALLY ENGINEERED MOUSE STRAIN; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; IMMUNOTHERAPY; LONG TERM SURVIVAL; MELANOMA; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TRANSGENIC MOUSE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY; NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84891128326     PISSN: 0959437X     EISSN: 18790380     Source Type: Journal    
DOI: 10.1016/j.gde.2013.11.008     Document Type: Review

References (23)

1. Callahan M.K., Postow M.A., Wolchok J.D. Immunomodulatory therapy for melanoma: ipilimumab and beyond. Clin Dermatol 2013, 31:191-199.
2. Zhou G., Levitsky H. Towards curative cancer immunotherapy: overcoming posttherapy tumor escape. Clin Dev Immunol 2012, 2012:124187.
3. Coley W.B. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res 1991, 3-11.
4. Foley E.J. Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res 1953, 13:835-837.
5. Little C.C. A Possible mendelian explanation for a type of inheritance apparently non-mendelian in nature. Science 1914, 40:904-906.
6. Prehn R.T., Main J.M. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 1957, 18:769-778.
7. Burnet F.M. The concept of immunological surveillance. Prog Exp Tumor Res 1970, 13:1-27.
8. Thomas L. On immunosurveillance in human cancer. Yale J Biol Med 1982, 55:329-333.
9. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565-1570.
10. Stutman O. Chemical carcinogenesis in nude mice: comparison between nude mice from homozygous matings and heterozygous matings and effect of age and carcinogen dose. J Natl Cancer Inst 1979, 62:353-358.
11. Nishikawa H., Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer 2010, 127:759-767.
12. Solito S., Bronte V., Mandruzzato S. Antigen specificity of immune suppression by myeloid-derived suppressor cells. J Leukoc Biol 2011, 90:31-36.
13. Andersen M.H., Schrama D., Thor Straten P., Becker J.C. Cytotoxic T cells. J Invest Dermatol 2006, 126:32-41.
14. Holland E.C. Mouse Models of Human Cancer 2004, Wiley-Liss, Hoboken, NJ.
15. McMahon M., Dankort D., Curley D., Filenova E., Bosenber M. A new mouse model of BRafV600E-induced metastatic melanoma. SMR emtting. Pigment Cell Res 2007, 20.
16. Carreno B.M., Garbow J.R., Kolar G.R., Jackson E.N., Engelbach J.A., Becker-Hapak M., Carayannopoulos L.N., Piwnica-Worms D., Linette G.P. Immunodeficient mouse strains display marked variability in growth of human melanoma lung metastases. Clin Cancer Res 2009, 15:3277-3286.
17. Ito M., Hiramatsu H., Kobayashi K., Suzue K., Kawahata M., Hioki K., Ueyama Y., Koyanagi Y., Sugamura K., Tsuji K., et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 2002, 100:3175-3182.
18. Shultz L.D., Lyons B.L., Burzenski L.M., Gott B., Chen X., Chaleff S., Kotb M., Gillies S.D., King M., Mangada J., et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 2005, 174:6477-6489.
19. McDermott S.P., Eppert K., Lechman E.R., Doedens M., Dick J.E. Comparison of human cord blood engraftment between immunocompromised mouse strains. Blood 2010, 116:193-200.
20. Wolchok J.D., Kluger H., Callahan M.K., Postow M.A., Rizvi N.A., Lesokhin A.M., Segal N.H., Ariyan C.E., Gordon R.A., Reed K., et al. Nivolumab plus ipilimumab in advanced melanoma. The New England journal of medicine 2013, 369:122-133.
21. Callahan M.K., Masters G., Pratilas C.A., Ariyan C.E., Katz J., Kitano S., Russell V., Gordon R.A., Vyas S., Yuan J., et al. Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor. Cancer Immunol Res 2013.
22. Ribas A., Hodi F.S., Callahan M., Konto C., Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. New Engl J Med 2013, 368:1365-1366.
23. Grupp S.A., June C.H. Adoptive cellular therapy. Curr Top Microbiol Immunol 2011, 344:149-172.